Atossa Genetics Inc (ATOS)vsVertex Pharmaceuticals Inc (VRTX)
ATOS
Atossa Genetics Inc
$2.45
+4.70%
HEALTHCARE · Cap: $20.46M
VRTX
Vertex Pharmaceuticals Inc
$503.50
-0.24%
HEALTHCARE · Cap: $130.87B
Smart Verdict
WallStSmart Research — data-driven comparison
VRTX leads profitability with a 35.0% profit margin vs 0.0%. VRTX earns a higher WallStSmart Score of 64/100 (C+).
ATOS
Avoid27
out of 100
Grade: F
VRTX
Buy64
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for ATOS.
Margin of Safety
+45.0%
Fair Value
$957.59
Current Price
$503.50
$454.09 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Keeps 35 of every $100 in revenue as profit
Strong operational efficiency at 38.1%
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Large-cap with strong market position
Every $100 of equity generates 22 in profit
Areas to Watch
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Expensive relative to growth rate
Premium valuation, high expectations priced in
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : ATOS
The strongest argument for ATOS centers on Price/Book.
Bull Case : VRTX
The strongest argument for VRTX centers on Profit Margin, Operating Margin, Debt/Equity. Profitability is solid with margins at 35.0% and operating margin at 38.1%. Revenue growth of 12.5% demonstrates continued momentum.
Bear Case : ATOS
The primary concerns for ATOS are Revenue Growth, EPS Growth, Market Cap.
Bear Case : VRTX
The primary concerns for VRTX are PEG Ratio, P/E Ratio, Piotroski F-Score.
Key Dynamics to Monitor
ATOS profiles as a value stock while VRTX is a mature play — different risk/reward profiles.
ATOS carries more volatility with a beta of 1.27 — expect wider price swings.
VRTX is growing revenue faster at 12.5% — sustainability is the question.
VRTX generates stronger free cash flow (1.0B), providing more financial flexibility.
Bottom Line
VRTX scores higher overall (64/100 vs 27/100), backed by strong 35.0% margins and 12.5% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Atossa Genetics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops drugs in the areas of oncology and infectious diseases. The company is headquartered in Seattle, Washington.
Vertex Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Vertex Pharmaceuticals, Inc. is an American biopharmaceutical company based in Boston, Massachusetts.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?